Selenium and breast cancer risk: A prospective nested case–control study on serum selenium levels, smoking habits and overweight

Sandsveden, Malte; Manjer, Jonas

doi:10.1002/ijc.30875

Cited by 18 publications

(19 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to breast cancer, prospective studies have generally reported no association between blood or toenail selenium levels and risk [9, 20–23]. In our study, breast cancer was the most commonly diagnosed cancer, followed by cancers of the lung and colon.…”

Section: Discussionmentioning

confidence: 38%

Serum selenium level and cancer risk: a nested case-control study

Narod

Huzarski

Jakubowska

et al. 2019

Hered Cancer Clin Pract

View full text Add to dashboard Cite

BackgroundEpidemiologic studies have demonstrated a relationship between selenium status and cancer risk among those with low selenium levels. It is of interest to prospectively evaluate the relationship between selenium and cancer among women who reside in a region with ubiquitously low selenium levels.MethodsWe performed a nested case-control study of baseline serum selenium levels and cancer risk using data and biological samples from 19,573 females that were participants in a biobanking initiative between 2010 and 2014 in Szczecin Poland. Cases included women with any incident cancer (n = 97) and controls (n = 184) were women with no cancer at baseline or follow-up. Serum selenium was quantified using mass spectroscopy.ResultsThe odds ratio associated being below the cutoff of 70.0 μg/L compared to a level above 70.0 μg/L was 2.29 (95% CI 1.26–4.19; P = 0.007). The risks for women in the two middle categories were similar and suggests that the normal range be between 70 μg/L and 90 μg/L. There was evidence for an increased risk of cancer among women in the highest category of selenium levels (i.e., > 90 μg/L), but this association did not achieve statistical significance (OR = 1.63; 95%CI 0.63–4.19; P = 0.31).ConclusionsResults from this study suggest that suggest that the optimum serum level of selenium in women living in Poland should be between 70 μg/L and 90 μg/L.

show abstract

Section: Discussionmentioning

confidence: 38%

Serum selenium level and cancer risk: a nested case-control study

Narod

Huzarski

Jakubowska

et al. 2019

Hered Cancer Clin Pract

View full text Add to dashboard Cite

show abstract

“…Selenium (Se) has been studied regarding a protective effect against breast cancer risk and these studies have rendered mixed but mainly null results 1,2 . Our results from a previous study, as well as a recent Cochrane systematic review, suggest that it is unlikely that Se is associated with the overall risk of breast cancer 2,3 . However, two studies have reported increased breast cancer mortality among women in the lowest quartile of serum Se as well as Se intake, and thus a potential protective effect of Se might be seen in clinical outcome rather than in incidence 4,5 …”

Section: Introductionmentioning

confidence: 72%

Prediagnostic serum selenium levels in relation to breast cancer survival and tumor characteristics

Sandsveden

Nilsson

Borgquist

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Women with lower levels of serum selenium (Se) may have a worse survival in breast cancer than women with higher levels, despite no difference in incidence of the disease. Our study was conducted to test whether Se is associated with the aggressiveness of breast tumors. Both the risk of having a tumor characteristic associated with worse prognosis, as well as the overall and breast cancer‐specific mortality, were studied. We identified breast cancer cases and controls within the Malmö Diet and Cancer Study, a population‐based cohort with 17 035 women recruited between 1991 and 1996. Inclusion criteria were incident breast cancer. Exclusion criteria were carcinoma in situ and bilateral breast cancer. Controls were selected among breast cancer‐free women both from matching (n = 694) as well as randomization (n = 492). After exclusion, 1066 cases remained and were compared to controls regarding their prediagnostic serum Se levels and subsequent risk of having a certain tumor characteristic or intrinsic subtype. We also followed breast cancer patients regarding overall and breast cancer‐specific mortality, comparing different Se quartiles. No association between serum Se quartile and any tumor characteristic or intrinsic subtype was found. Lower overall mortality was found among women in the highest Se quartile compared to the lowest using an adjusted Cox proportional hazards model, hazard ratio 0.63 (95% confidence interval: 0.44‐0.89). Similar results were seen for breast cancer‐specific mortality, 0.60 (0.37‐0.98). The results of our study support that Se is associated with a lower mortality in breast cancer, not related to established prognostic factors.

show abstract

“…As previously described by Sandsveden et al [2], the saved serum was analyzed by ALS Scandinavia AB, Luleå, Sweden. A total of 262 women lacked the necessary amount of stored serum and therefore could not be included in the analyses.…”

Section: Laboratory Methodsmentioning

confidence: 99%

“…We have previously reported on the association between pre-diagnostic serum selenium and breast cancer risk [2]. The aim of the current study was to examine breast cancer risk related to pre-diagnostic levels of dietary intake of selenium within MDCS.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Risk of breast cancer in relation to dietary intake of selenium and serum selenium as a marker of dietary intake: a prospective cohort study within The Malmö Diet and Cancer Study

Bengtsson

Sandsveden

Manjer

2021

Cancer Causes Control

Self Cite

View full text Add to dashboard Cite

Purpose Selenium has been suggested to be protective against breast cancer, but the evidence remains inconclusive. Hence, it is important to further examine the potential protective effect. This prospective cohort study investigates pre-diagnostic selenium intake in relation to breast cancer risk. In addition, we analyze serum selenium as a marker of dietary intake. Methods This study includes 17,035 women in the Malmö Diet and Cancer cohort. Dietary assessment and serum samples were collected at baseline (1991–1996). During 344,584 person-years of follow-up, 1,427 incident cases were retrieved. Cox regression analysis examined breast cancer risks adjusted for potential confounding factors. In addition, odds ratios (ORs) were estimated for 1186 cases and an equal number of controls in relation to quartiles (Q) of selenium intake and groups consisting of a combination of intake and serum selenium levels. Results No overall association between selenium intake, or a combination of intake and serum levels, and breast cancer risk was found. The adjusted relative risk for breast cancer in selenium intake Q4 versus Q1 was 0.96 (0.83–1.12) (Ptrend = 0.65). Similarly, adjusted the OR for breast cancer in selenium intake for Q4 versus Q1 was 0.97 (0.76–1.23). The kappa value, 0.096 (p = 0.001), showed poor agreement between serum selenium and selenium intake. Conclusion Our findings suggest that there is no overall association between selenium intake, or a combination of intake and serum levels, and breast cancer risk. Finally, our results showed a poor correlation between estimated selenium intake and serum selenium.

show abstract

Selenium and breast cancer risk: A prospective nested case–control study on serum selenium levels, smoking habits and overweight

Cited by 18 publications

References 48 publications

Serum selenium level and cancer risk: a nested case-control study

Serum selenium level and cancer risk: a nested case-control study

Prediagnostic serum selenium levels in relation to breast cancer survival and tumor characteristics

Risk of breast cancer in relation to dietary intake of selenium and serum selenium as a marker of dietary intake: a prospective cohort study within The Malmö Diet and Cancer Study

Contact Info

Product

Resources

About